Arena Pharmaceuticals Inc (NASDAQ:ARNA)
| 70.29 BATS BZX Real-Time Price As of 2:39pm ET |  -0.96 / -1.35%Today’s Change | 32.95 Today|||52-Week Range 72.30 | +54.76% Year-to-Date |
Latest ARNA News | Press Releases
| Arena Pharmaceuticals, Inc. (ARNA) CEO Amit Munshi Presents at Cantor 2020 Global Virtual Healthcare Conference (Transcript) Sep 16 / Seeking Alpha - Paid Partner Content | Arena Pharmaceuticals (ARNA) Investor Presentation - Slideshow Sep 11 / Seeking Alpha - Paid Partner Content |
| Dosing underway in Arena Pharma's pivotal etrasimod study in ulcerative colitis Sep 16 / Seeking Alpha - Paid Partner Content | Arena Pharmaceuticals, Inc.'s (ARNA) CEO Amit Munshi at Wells Fargo Securities 2020 Virtual Healthcare Conference (Transcript) Sep 10 / Seeking Alpha - Paid Partner Content |
| Arena Pharmaceuticals (ARNA) Investor Presentation - Slideshow Sep 15 / Seeking Alpha - Paid Partner Content | Dosing underway in mid-stage study of Arena's etrasimod in hair loss disorder Sep 01 / Seeking Alpha - Paid Partner Content |
| Arena Pharmaceuticals, Inc.'s (ARNA) CEO Amit Munshi at H.C. Wainwright Virtual Global Investment Conference Transcript Sep 14 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 71.25 |
| Today’s open | 69.68 |
| Day’s range | 69.52 - 71.39 |
| Volume | 26,508 |
| Average volume (3 months) | 703,699 |
| Market cap | $4.0B |
Data as of 2:39pm ET, 09/21/2020
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -198.82% |
| Earnings growth (next 5 years) | -55.39% |
| Revenue growth (last year) | +4,387.65% |
| P/E ratio | NM |
| Price/Sales | 2.91 |
| Price/Book | 3.27 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ALLKAllakos Inc | -4.82 | -5.72% |
| GRFSGrifols SA | -0.46 | -2.85% |
| ---- | ||
| CBPOChina Biologic Produ... | -1.46 | -1.30% |
Data as of 2:37pm ET, 09/21/2020
Financials
| Next reporting date | November 4, 2020 |
| EPS forecast (this quarter) | -$1.87 |
| Annual revenue (last year) | $806.4M |
| Annual profit (last year) | $397.6M |
| Net profit margin | 49.30% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
